In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Jean-Marc Classe to discuss the CHIPOR Trial. Dr. Classe is a surgeon and former head of the surgical department of the Institute of Surgical Oncology of Nantes, France. He is a professor in oncology and president of the French Society of Surgical Oncology.
- The CHIPOR phase III RCT studied the use of HIPEC in 1st PSROC who underwent complete cytoreductive op after 2nd-line platinum-based chemo. Randomization was performed during complete cytoreductive surgery.
- The primary endpoint was OS. Results showed HIPEC significantly improved OS, HR 0.69, p=0.020.
- This study suggests that HIPEC can be a beneficial addition to the tx strategy for women with 1st PSROC when used in conjunction with 2nd-line platinum-based chemo and complete cytoreductive surgery.